Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders

被引:33
作者
Donatti, Amanda [1 ,2 ]
Canto, Amanda M. [1 ,2 ]
Godoi, Alexandre B. [1 ,2 ]
Rosa, Douglas C. [1 ,2 ]
Lopes-Cendes, Iscia [1 ,2 ]
机构
[1] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Dept Med Genet & Genom Med, 126 Cidade Univ Zeferino Vaz, BR-13083887 Campinas, SP, Brazil
[2] Brazilian Inst Neurosci & Neurotechnol, BR-13083887 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
amyotrophic lateral sclerosis; Alzheimer's disease; epilepsy; multiple sclerosis; Parkinson's disease; stroke; metabolomics; mass spectrometry; magnetic nuclear resonance; AMYOTROPHIC-LATERAL-SCLEROSIS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ACUTE ISCHEMIC-STROKE; AMINO-ACID SIGNATURE; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; MASS-SPECTROMETRY; ALPHA-SYNUCLEIN; METABOLOMIC ANALYSIS;
D O I
10.3390/metabo10100389
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.
引用
收藏
页码:1 / 32
页数:32
相关论文
共 183 条
[1]   N8-acetylspermidine as a potential plasma biomarker for Snyder-Robinson syndrome identified by clinical metabolomics [J].
Abela, Lucia ;
Simmons, Luke ;
Steindl, Katharina ;
Schmitt, Bernhard ;
Mastrangelo, Massimo ;
Joset, Pascal ;
Papuc, Mihaela ;
Sticht, Heinrich ;
Baumer, Alessandra ;
Crowther, Lisa M. ;
Mathis, Deborah ;
Rauch, Anita ;
Plecko, Barbara .
JOURNAL OF INHERITED METABOLIC DISEASE, 2016, 39 (01) :131-137
[2]   CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].
ADAMS, HP ;
BENDIXEN, BH ;
KAPPELLE, LJ ;
BILLER, J ;
LOVE, BB ;
GORDON, DL ;
MARSH, EE ;
KASE, CS ;
WOLF, PA ;
BABIKIAN, VL ;
LICATAGEHR, EE ;
ALLEN, N ;
BRASS, LM ;
FAYAD, PB ;
PAVALKIS, FJ ;
WEINBERGER, JM ;
TUHRIM, S ;
RUDOLPH, SH ;
HOROWITZ, DR ;
BITTON, A ;
MOHR, JP ;
SACCO, RL ;
CLAVIJO, M ;
ROSENBAUM, DM ;
SPARR, SA ;
KATZ, P ;
KLONOWSKI, E ;
CULEBRAS, A ;
CAREY, G ;
MARTIR, NI ;
FICARRA, C ;
HOGAN, EL ;
CARTER, T ;
GURECKI, P ;
MUNTZ, BK ;
RAMIREZLASSEPAS, M ;
TULLOCH, JW ;
QUINONES, MR ;
MENDEZ, M ;
ZHANG, SM ;
ALA, T ;
JOHNSTON, KC ;
ANDERSON, DC ;
TARREL, RM ;
NANCE, MA ;
BUDLIE, SR ;
DIERICH, M ;
HELGASON, CM ;
HIER, DB ;
SHAPIRO, RA .
STROKE, 1993, 24 (01) :35-41
[3]   Response to drug treatment in newly diagnosed epilepsy: A pilot study of 1H NMR- and MS-based metabonomic analysis [J].
Al Zweiri, Muhammed ;
Sills, Graeme J. ;
Leach, John Paul ;
Brodie, Martin J. ;
Robertson, Chris ;
Watson, David G. ;
Parkinson, John A. .
EPILEPSY RESEARCH, 2010, 88 (2-3) :189-195
[4]   Metabolomics analysis: Finding out metabolic building blocks [J].
Alberich, Ricardo ;
Castro, Jose A. ;
Llabres, Merce ;
Palmer-Rodriguez, Pere .
PLOS ONE, 2017, 12 (05)
[5]   Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene [J].
Andersen, Peter M. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (01) :37-46
[6]   Metabolome-based signature of disease pathology in MS [J].
Andersen, S. L. ;
Briggs, F. B. S. ;
Winnike, J. H. ;
Natanzon, Y. ;
Maichle, S. ;
Knagge, K. J. ;
Newby, L. K. ;
Gregory, S. G. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 :12-21
[7]   Low plasma uric acid level in Parkinson's disease [J].
Annanmaki, Tua ;
Muuronen, Antti ;
Murros, Kari .
MOVEMENT DISORDERS, 2007, 22 (08) :1133-1137
[8]   Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury [J].
Arundine, M ;
Tymianski, M .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (06) :657-668
[9]   The Alzheimer's Disease Clinical Spectrum Diagnosis and Management [J].
Atri, Alireza .
MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (02) :263-+
[10]   Systematic Review: Clinical Metabolomics to Forecast Outcomes in Liver Transplantation Surgery [J].
Attard, Joseph A. ;
Dunn, Warwick B. ;
Mergental, Hynek ;
Mirza, Darius F. ;
Afford, Simon C. ;
Perera, Thamara P. R. .
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2019, 23 (10) :463-476